Disease areas

Neurology and pain

68 public biotech companies we cover are developing treatments for ALS, Alzheimer's, Parkinson's, multiple sclerosis, epilepsy, pain and other nervous system conditions. 45 upcoming catalysts are listed below, with dates as the companies gave them.

Companies

Drug pages

RelutrigineUlixacaltamideObecabtagene autoleucel (obe-cel)RexaceractMivocabtagene autoleucel (miv-cel)

Upcoming catalysts

Firm dates · a specific day set by the company or regulator

Next 90 days

Later

Estimated timing · a month, quarter, half-year or year-end the company gave

Expected in November 2026

  • November 2026
    Neflamapimod · Phase 2a interim results · Nonfluent variant primary progressive aphasia

Expected by end of November 2026

Expected in Q4 2026

Expected in H2 2026

Expected by end of 2026

Expected in January 2027

Expected in Q1 2027

Expected in Q2 2027

Expected in H1 2027

Expected by end of June 2027

Expected in July 2027

Expected in Q3 2027

Other disease areas